louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05449652: Exercise Prescriptions for Patients With Cardiovascular Disease
Official title: Are Exercise Prescriptions for Patients With Cardiovascular Disease, Made by Physiotherapists, in Agreement With International Guidelines?
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cardiovascular Diseases
Keywords: physiotherapy
exercise prescription
cardiovascular disease
Lead sponsor: Hasselt University
Sponsor class: OTHER
First posted: 2022-07-08
Enrollment: 47
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Professionaly active Flemish physiotherapists.

Brief summary: Physiotherapists are often confronted with patients with (elevated risk for) cardiovascular disease (CVD), even when this is not the primary indication for physiotherapy. Hence, physiotherapists should be able to provide evidence-based exercise advice to these patients, but this has not been assessed. The aim of this study was therefore to assess whether exercise prescriptions by physiotherapists to patients with CVD are in accordance with international recommendations.

Detailed description: In this prospective observational survey, forty-seven Belgian physiotherapists agreed to prescribe exercise intensity, frequency, session duration, program duration, and exercise type (endurance or strength training) for the same three patient cases. Exercise prescriptions were compared between clinicians and relations with clinician characteristics were studied. In addition, the agreement between physiotherapists' exercise prescriptions and those from international recommendations (based on a maximal score of 60/per case) was assessed.

Eligibility criteria: Inclusion Criteria: Currently professionally active Flemish physiotherapists

Exclusion Criteria: Not having access to a device that allows the use of the EXercise Prescription in Everyday practice \& Rehabilitative Training (EXPERT) tool.

Primary outcomes:
measure: Exercise intensity
timeFrame: February - April 2022
measure: Exercise frequency
timeFrame: February - April 2022
measure: Session duration
timeFrame: February - April 2022
measure: Program duration
timeFrame: February - April 2022
measure: Exercise type
timeFrame: February - April 2022
measure: Total exercise volume
timeFrame: February - April 2022
Secondary outcomes:
measure: Association between exercise prescriptions and clinician characteristics'
timeFrame: February - April 2022
Other outcomes:
Locations:
city: Diepenbeek
country: Belgium
facility: Hasselt University
state: Limburg
Study officials:
affiliation: Hasselt University
name: Dominique Hansen, Prof
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00305552: SARCOTHAL. Thalidomide in Skin Sarcoidosis
Official title: Randomized Controlled Trial of Thalidomide vs Placebo in Skin Sarcoidosis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Sarcoidosis
Keywords: Randomized controlled trial
Thalidomide vs placebo
skin sarcoidosis
Thalidomide
Lead sponsor: Assistance Publique - Hôpitaux de Paris
Sponsor class: OTHER
First posted: 2006-03-22
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Sarcoidosis is a multisystem disease involving most frequently the lung, the eyes, the lymph nodes and the skin. Skin lesions may be disfiguring and impair the quality of life. Thalidomide is a multi-target drug that has been shown to be of benefit in skin sarcoidosis in case reports. The objective is to assess the efficacy and tolerance of thalidomide in skin sarcoidosis.

Detailed description: The study consists in comparing thalidomide to placebo in skin sarcoidosis. Patients with sarcoidosis not necessitating a high-dose corticosteroid regimen, and assessable skin lesions, are eligible. They are randomized and receive either thalidomide or placebo for 3 months. Then they are given Thalidomide for a 3-month open-label period.

Eligibility criteria: Inclusion Criteria:

* Biopsy proven skin sarcoidosis
* Assessable target skin lesions

Exclusion Criteria:

* Rapidly evolving sarcoidosis
* Patients necessitating a corticosteroid regimen of more than 15mg per day.
* Women not willing to undertake a contraceptive method.
* Neurologic impairment
* Past treatment with Thalidomide
* Renal impairment

Primary outcomes:
measure: Size of target skin lesions at 3 months.
timeFrame: during de study
Secondary outcomes:
measure: Physician global assessment at 3 months. Functional assessment of other organs. Side-effects at 3 months.
timeFrame: during the study
Other outcomes:
Locations:
city: Paris
country: France
facility: HOPITAL Saint Louis, Service de Dermatologie
Study officials:
affiliation: Assistance Publique - Hôpitaux de Paris
name: Michel RYBOJAD, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Droitcourt C, Rybojad M, Porcher R, Juillard C, Cosnes A, Joly P, Lacour JP, D'Incan M, Dupin N, Sassolas B, Misery L, Chevrant-Breton J, Lebrun-Vignes B, Desseaux K, Valeyre D, Revuz J, Tazi A, Chosidow O, Dupuy A. A randomized, investigator-masked, double-blind, placebo-controlled trial on thalidomide in severe cutaneous sarcoidosis. Chest. 2014 Oct;146(4):1046-1054. doi: 10.1378/chest.14-0015.
Clinical trial NCT00527852: Assessment of Flocked Swabs for the Identification of Group A Streptococcal Pharyngitis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Streptococcal Infection
Pharyngitis
Keywords: Flocked swab
Group A streptococcus pharyngitis
Lead sponsor: Children's Hospital of Eastern Ontario
Sponsor class: OTHER
First posted: 2007-09-11
Enrollment: 350
Sex: ALL
Minimum age (years): 1
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: This is a study to to compare traditional fibre wound swabs to more recently developed flocked swabs for the identification of Group A streptococcal pharyngitis in children presenting to a children's emergency department.


Eligibility criteria: Inclusion Criteria:

* Need for a bacterial throat culture

Primary outcomes:
measure: Identification of Group A streptococcus via culture of organism
Secondary outcomes:
Other outcomes:
Locations:
city: Ottawa
country: Canada
facility: Children's Hospital of Eastern Ontario Emergency Department
state: Ontario
Study officials:
affiliation: Children's Hospital of Eastern Ontario, Division of Infectious Disease
name: David M Goldfarb, MD FRCPC
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00929552: Effect of Fish Oil on Markers of the Metabolic Syndrome in Overweight Adolescent Boys
Official title: Effect of n-3 LCPUFAs on Weight Reduction and Metabolic Syndrome.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Metabolic Syndrome
Keywords: Blood pressure
Insulin sensitivity
Blood lipid profile
Lead sponsor: University of Copenhagen
Sponsor class: OTHER
First posted: 2009-06-29
Enrollment: 78
Sex: MALE
Minimum age (years): 13
Maximum age (years): 15
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The aim of the study is to investigate if dietary fish oil has a beneficial effect on blood pressure, insulin sensitivity, blood lipid profile, body composition and metabolic rate in healthy, but slightly overweight, teenage boys.

We hypothesized that the n-3 long chain polyunsaturated fatty acids from fish oil might have greater effect during growth and development, as intervention trials studying the effect of fish oil on babies have shown greater effects than in adults.


Eligibility criteria: Inclusion Criteria:

* Weight above the 90th percentile for height and age.

Exclusion Criteria:

* Smoking, severe illnesses.

Primary outcomes:
measure: Markers of the metabolic syndrome. Blood pressure, insulin sensitivity, HDL-cholesterol and triacylglycerol.
timeFrame: Intervention period = 16 weeks
Secondary outcomes:
measure: Body composition
timeFrame: 16 weeks
Other outcomes:
Locations:
city: Frederiksberg
country: Denmark
facility: Department of Human Nutrition
Study officials:
affiliation: University of Copenhagen
name: Lotte Lauritzen, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Pedersen MH, Molgaard C, Hellgren LI, Lauritzen L. Effects of fish oil supplementation on markers of the metabolic syndrome. J Pediatr. 2010 Sep;157(3):395-400, 400.e1. doi: 10.1016/j.jpeds.2010.04.001. Epub 2010 May 15.
Clinical trial NCT00071552: Efficacy of QVAR vs Flovent Diskus on Small Airways in Poorly Controlled Asthmatic Adolescents/Adult Patients
Official title: Evaluation of Clinical Efficacy of HFA-Propelled Beclomethasone Dipropionate Metered-Dose Inhaler Versus Fluticasone Propionate Multidose Dry Powder Inhaler on Small Airways in Poorly Controlled Asthmatic Adolescent and Adult Patients
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE4
Conditions: Asthma
Keywords: Poorly Controlled Asthma
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.
Sponsor class: INDUSTRY
First posted: 2003-10-29
Enrollment: 49
Sex: ALL
Minimum age (years): 12
Maximum age (years): 70
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The primary objective of this study is to evaluate the effect of Beclomethasone dipropionate HFA on small airways compared to Fluticasone propionate powder for inhalation administered twice daily to poorly controlled asthmatics.


Eligibility criteria: Inclusion Criteria:

* Poorly controlled asthma;
* Average use of over 2 puffs of albuterol per day in the previous 7 days OR Having symptoms of asthma on 5 of the last 7 days OR Awakening at night due to asthma at least once in the previous 7 days OR Having been treated with a course of oral or intravenous steroids at least once in the last 3 months.

Exclusion Criteria:

* Subjects receiving escalating doses of immunotherapy, oral immunotherapy or short course (rush) immunotherapy for rhinitis;
* Requires beta-blockers, MAO inhibitors, tricyclic antidepressants, oral or intranasal anticholinergics;
* History and/or presence of any non-asthmatic acute or chronic lung disease, including but not limited to bronchitis, emphysema, active tuberculosis, bronchiectasis or cystic fibrosis;
* History and/or presence of any clinically significant cardiovascular disease, clinically significant hepatic, renal, or endocrine dysfunction, stroke, uncontrolled diabetes, hyperthyroidism, convulsive disorders, neoplastic disease other than basal cell carcinoma, and significant psychiatric disease.

Primary outcomes:
measure: Change in post-inhalation percent-predicted FEF 25-75 (%) from baseline (week 0) to week 12
timeFrame: Final Visit
Secondary outcomes:
measure: Mean and mean change from pre-dose to 15-minute post-dose in percent predicted FEV1 (%) at week 12
timeFrame: week 12
Other outcomes:
Locations:
city: Denver
country: United States
facility: National Jewish Medical and Research Center
state: Colorado
Study officials:
References:
Clinical trial NCT02117752: Dermal Tolerability of Dapsone Gel in Healthy Volunteers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy Volunteers
Lead sponsor: Almirall, S.A.
Sponsor class: INDUSTRY
Collaborators: name: Allergan
First posted: 2014-04-21
Enrollment: 237
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study will determine the cumulative irritation potential and sensitization potential of dapsone gel and vehicle after repeat applications on the skin of healthy volunteers.


Eligibility criteria: Inclusion Criteria:

-Healthy adults.

Exclusion Criteria:

* Skin diseases, excessive hair, tattoos, pigmentation, scars or moles that could interfere with patch application
* Sensitivity to adhesive bandages or tape.

Primary outcomes:
measure: Mean Cumulative Irritation Index During Induction Phase
timeFrame: 21 Days
measure: Incidence of Sensitization Reactions During Challenge Phase
timeFrame: 6 Weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Fair Lawn
country: United States
state: New Jersey
Study officials:
affiliation: Allergan
name: Medical Director
role: STUDY_DIRECTOR
References:
Clinical trial NCT02549352: Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month Follow-up
Official title: Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month Follow-up
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Actinic Keratosis
Lead sponsor: LEO Pharma
Sponsor class: INDUSTRY
First posted: 2015-09-15
Enrollment: 391
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The objective of the trial is to compare the short term efficacy of LEO 43204 gel with vehicle gel in AK on the balding scalp when applied topically once daily for 3 consecutive days as field treatment


Eligibility criteria: Inclusion Criteria:

* Subjects with 5 to 20 clinically typical, visible and discrete AKs within a treatment area of sun-damaged skin on the full balding scalp (the balding part of the scalp should be greater than 25 cm2 (4 in2) and up to approximately 250 cm2 (40 In2)
* Subjects with minimum 3 clinically typical, visible and discrete AKs within a tracking area of 50 cm2 (8 In2). The tracking area must be within the treatment area

Exclusion Criteria:

* Location of the treatment area (balding scalp) within 5 cm of an incompletely healed wound or within 5 cm of a suspected BCC or SCC
* Treatment with ingenol mebutate gel in the treatment area within the last 12 months
* Lesions in the treatment area that have: atypical clinical appearance (e.g. hyperthrophic, hyperkeratotic or cutaneous horns) and /or, recalcitrant disease (e.g. did not respond to cryotherapy on two previous occasions)
* History or evidence of skin conditions other than the trial indication that would interfere with the evaluation of the trial medication (e.g. eczema, unstable psoriasis, xeroderma pigmentosum)

Primary outcomes:
measure: Percentage of Participants With Complete Clearance of Actinic Keratosis (AK)
timeFrame: At Week 8
Secondary outcomes:
measure: Percentage of Participants With Partial Clearance
timeFrame: At Week 8
measure: Percentage of Participants With Partial Clearance
timeFrame: At Week 4
measure: Percent Reduction in AK Count in the Treatment Area Compared to Baseline
timeFrame: At Week 8
Other outcomes:
Locations:
city: Recklinghausen
country: Germany
facility: Klinik für Dermatologie & Allergologie Klinikum Vest GmbH
Study officials:
affiliation: Klinik für Dermatologie & Allergologie Klinikum Vest GmbH
name: Rolf-Markus Szeimies, Prof. Dr.med
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01613352: Feasibility of Ambulatory Surgery for Early Breast Cancer
Official title: Same Day Discharge After Surgery for Early Breast Cancer - a Feasible Option
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Early Breast Cancer
Psychosocial Wellbeing
Ambulatory Surgery
Keywords: Early breast cancer surgery
Psychosocial wellbeing
Ambulatory surgery
Lead sponsor: Helsinki University Central Hospital
Sponsor class: OTHER
First posted: 2012-06-07
Enrollment: 100
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: The aim was to assess the patient compliance and medical and psychosocial effects of same day hospital discharge after breast conserving surgery and sentinel node biopsy only.

Detailed description: The patients with small breast tumours (\<2 cm)and clinically node negative disease, were randomized to receive breast conserving surgery and sentinel node biopsy as ambulatory surgery or inpatient-surgery.Complication rate, patient satisfaction and psychosocial outcomes were compared. The psychosocial effects of the treatment mode on their spouses were recorded as well.

Eligibility criteria: Inclusion Criteria:

* Breast cancer \< 2cm
* Clinically node negative
* ASA I-II

Exclusion Criteria:

* Axillary clearance performed
* ASA III-IV
* No adult companion at home

Primary outcomes:
measure: Psychosocial wellfare
timeFrame: First postoperative day
Secondary outcomes:
measure: Number of complications and return to hospital rate
timeFrame: one week
Other outcomes:
Locations:
city: Espoo
country: Finland
facility: Helsinki University Central Hospital, Jorvi Hospital
state: HUS
Study officials:
affiliation: Helsinki University Central Hospital, Jorvi Hospital
name: Jaana H Vironen, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Ojala K, Vironen JH, Mattila K, Eklund AM, Leidenius MH, Meretoja TJ. Feasibility of Day Surgery in Patients With Breast Conservation and Sentinel Node Biopsy: A Randomized Controlled Trial. Scand J Surg. 2016 Mar;105(1):29-34. doi: 10.1177/1457496915583201. Epub 2015 Apr 28.
Clinical trial NCT01472952: System-level Monitoring of Immune Activation Concerning Susceptibility to Sepsis in Trauma Patients
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Trauma
Sepsis
Keywords: sepsis
immune cells
immune reaction
trauma
Immune activation
Lead sponsor: Universitätsmedizin Mannheim
Sponsor class: OTHER
First posted: 2011-11-17
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Critical care patients with multiple trauma

Brief summary: Sepsis remains a common entity in critical care patients with remarkable mortality. Despite extended research activities, no reliable bio-markers or scoring systems attributing the individual risk of developing sepsis have been found so far.

Patients with multiple trauma are at high risk of developing sepsis. Due to local and systemic immune reactions, high plasma levels of known pro-inflammatory cytokines can be found.

Simultaneously, certain anti-inflammatory reactions such as changes in immune cell activity and serum cytokine levels, known as "compensatory anti-inflammatory response syndrome" (CARS) take place.

In addition to changes of cytokine levels and immune cell activity, underlying genetic reactions are present. For instance, expression of miRNA (as an potential important step of immune cell activation) is likely changed during systemic and local immune reactions.

In the present study levels of pro- and antiinflammatory cytokines, a detailed assay of immune cell activation and the various expression of miRNA will be evaluated in patients of multiple trauma on day 1 and day 4.

Additionally, clinical parameters of organ function, current infection markers as CRP and Procalcitonin, cardiovascular function such as Indocyanin clearance and hemodynamic measures delivered with PiCCO-system and heart rate variability will be assessed. Parameters of local tissue perfusion will be measured with transcutaneous laser doppler.


Eligibility criteria: Inclusion Criteria:

* multiple trauma,
* ISS \> 16

Exclusion Criteria:

* resuscitation
* pregnancy
* malignancy
* chronic renal insufficiency
* steroid intake

Primary outcomes:
measure: Sepsis
timeFrame: 14 days
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06913452: Effect of Obesity on Tear Film and Ocular Health Among Diabetic Patients
Official title: Effect of Obesity on Tear Film and Ocular Health Among Diabetic Patients
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Tear Film Deficiency
Lead sponsor: Superior University
Sponsor class: OTHER
First posted: 2025-04-06
Enrollment: 120
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Diabetic participants aged 18-70 with varying BMI categories will be assessed for tear production and film stability using Schirmer's Test and Tear Break-Up Time (TBUT). Demographics, medical history, and ocular health will also be recorded in a controlled clinic environment.

Brief summary: To evaluate the effect of obesity on tear film and ocular health in diabetic patients.

Research Design An observational cross-sectional study will be conducted.


Eligibility criteria: Inclusion Criteria:

* Adults (18+ years)
* diagnosed with type 1 or type 2 diabetes
* categorized as obese or non-obese (BMI \>30 or \<30)
* stable glycemic control, and willing to provide consent.

Exclusion Criteria:

* Non-diabetic individuals
* pregnant/lactating women
* those with recent ocular surgeries
* systemic medications affecting tear film, or severe unrelated diseases.

Primary outcomes:
measure: The Oswestry Disability Index (ODI)
timeFrame: 12 Months
Secondary outcomes:
Other outcomes:
Locations:
city: Mandi Bahāuddīn
country: Pakistan
facility: Alvi Hospital
state: Punjab
Study officials:
References: